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Abstract.  Tyrosine phosphorylation of multiple plate- 
let proteins is stimulated by thrombin and other 
agonists that cause platelet aggregation and secretion. 
The phosphorylation of a subset of these proteins, in- 
cluding a protein tyrosine kinase, pp125 FAK, is depen- 
dent on the platelet aggregation that follows  fibrinogen 
binding to integrin C~m~3. In this report, we examined 
whether fibrinogen binding, per se, triggers a process 
of tyrosine phosphorylation in the absence of exoge- 
nous agonists. Binding of soluble fibrinogen was in- 
duced with Fab fragments of an anti-~3 antibody (anti- 
LIBS6) that directly exposes the fibrinogen binding 
site in otm~3 Proteins of 50-68 kD and 140 kD be- 
came phosphorylated on tyrosine residues in a 
fibrinogen-dependent manner. This response did not 
require prostaglandin synthesis, an increase in cyto- 
solic free calcium, platelet aggregation or granule 
secretion, nor was it associated with tyrosine phos- 
phorylation of pp125 FA~. Tyrosine phosphory- 
lation of the 50-68-kD and 140-kD  proteins was 
also observed when (a) fibrinogen binding was stimu- 
lated by agonists such as epinephrine, ADP, or throm- 
bin instead of by anti-LIBS6; (b) fragment X, a di- 
meric plasmin-derived fragment of fibrinogen was 
used instead of fibrinogen; or (c) t~3  complexes 
were cross-linked by antibodies, even in the absence of 
fibrinogen. In contrast, no tyrosine phosphorylation 
was observed when the ligand consisted of monomeric 
cell recognition peptides derived from fibrinogen 
(RGDS or T4°°-4u). Fibrinogen-dependent tyrosine 
phosphorylation was inhibited by cytochalasin D. 
These studies demonstrate that fibrinogen binding to 
O/I~3 initiates a process of tyrosine phosphorylation 
that precedes platelet aggregation and the phosphoryla- 
tion of pp125 FAr. This reaction may depend on the 
oligomerization of integrin receptors and on the state 
of actin polymerization, organizational processes that 
may juxtapose tyrosine kinases with their substrates. 
I 
NTEGRINS are a family of heterodimeric (o~/) adhesion 
receptors that mediate cell-ceLl and cell-matrix interac- 
tions (32, 53).  Their expression on human platelets is 
critical  for hemostasis because they mediate the formation 
of platelet plugs at sites of vascular injury (28, 35, 43, 45). 
One of these integrins,  O/llb/~3, Can recognize several adhe- 
sive  ligands  containing the arginine-glycine-aspartic  acid 
(RGD) 1 cell  recognition sequence (e.g.,  fibrinogen,  von 
Willebrand factor, fibronectin, vitronectin).  Ligand binding 
to Ct~b/33 promotes two key aspects of platelet plug forma- 
tion.  First, the binding of plasma fibrinogen or von Wille- 
brand factor is essential  for platelet-to-platelet  aggregation 
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1. Abbreviations  used in this paper: RIPA, radioimmunoprecipitation assay; 
RGD,  single letter amino acid code for arginine-glycine-aspartic acid. 
(3,  12). Second, interaction of Ot~bl33 with immobilized von 
Willebrand factor or fibrinogen results in platelet spreading 
on the adhesive surface (46). Platelet spreading is associatexl 
with the assembly of actin filaments and other cytoskeletal 
proteins beneath the plasma membrane (25, 40).  These as- 
semblies may be analogous to the focal adhesions observed 
in cultured fibroblasts, sites at the cell-substratum  interface 
where  integrins  cluster  and  link  extracellular  adhesive 
ligands with the actin-rich cytoskeleton (58). 
Integrin c~ and/$ subunits each contain a large, globular 
extracellular domain, a single a-helical membrane-spanning 
domain and a relatively short cytoplasmic tail (31). In the 
case of ot~ and /~3, 95 % of each subunit  is extracellular, 
while the cytoplasmic tails contain only 20 and 41  amino 
acids, respectively (18, 44). The cytoplasmic tails of t~nb/33 
and other integrins may play pivotal roles in adhesion by (a) 
regulating  the ligand-binding  function of the extracellular 
domains through responses to intracellular signals ("inside- 
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and other intracellular molecules that may be involved in sig- 
nal transduction triggered by ligand binding ("outside-in" sig- 
naling).  Inside-out signaling  has profound implications  for 
circulating  platelets  since only platelets  activated by ago- 
nists, such as thrombin,  are able to bind soluble fibrinogen 
or von Willebrand factor (3, 43). 
Evidence for outside-in signaling by integrin receptors is 
accumulating in several cell systems, including platelets (31, 
33). For example, the adhesion of fibroblasts to fibronectin 
or fibronectin fragments has been shown to stimulate protein 
tyrosine phosphorylation,  an increase  in intracellular  pH, 
and upregulation of genes that control the G1/S cell cycle and 
the  synthesis  of metalloproteinases  (24,  48,  56,  60,  61). 
However, unlike growth factor receptors, which initiate sig- 
naling through the intrinsic protein tyrosine kinase activity 
of their cytoplasmic tails, integrins contain no such activity. 
Thus,  integrins  must initiate the process of tyrosine phos- 
phorylation indirectly, perhaps by modifying the activity or 
subcellular  localization  of non-receptor  tyrosine  kinases, 
tyrosine phosphatases,  or their substrates.  In this context, 
fibroblasts and other cell types have been shown to contain 
a  novel protein tyrosine kinase,  pp125  FAK, which localizes 
to  focal  adhesions  and  becomes activated  when  the  c~sfl~ 
fibronectin  receptor  is  engaged  by  fibronectin  or  cross- 
linked by antibodies (7, 8, 23, 34, 47, 62). Although the sub- 
strates for pp125 F^K have not been identified, it is hypothe- 
sized that this enzyme plays a role in linking adhesive events 
at the cell surface with intracellular events required for cell 
function. 
Platelets are an excellent model system to study some of 
the  functional  implications  of integrin-mediated  signaling 
since their physiology is well understood and they have not 
been exposed to the perturbations of tissue culture. Activa- 
tion of platelets by thrombin  or ADP results in the phos- 
phorylation  of numerous proteins  ranging  in size on SDS 
gels  from  30-140  kD,  including  pp125 FAK  (17, 21,  36). 
Moreover, the phosphorylation of pp125  FAK and at least two 
other proteins with molecular masses of ml00 kD is depen- 
dent  on  platelet  aggregation  mediated  by  fibrinogen  and 
O~rd33 (16, 22,  36).  Therefore,  platelets have been used in 
the present study to better define the sequence of events be- 
tween ligand binding to an integrin and tyrosine phosphory- 
lation  of pp125 FAK. Our approach  was to ask whether  the 
binding of soluble fibrinogen to O(IIb~3 was  sufficient to trig- 
ger  protein  tyrosine phosphorylation  in  the  absence  of a 
platelet agonist and without platelet aggregation.  Fab frag- 
ments  of an  antibody  specific for  the  /33 integrin  subunit 
were used to induce fibrinogen binding without antecedent 
platelet activation.  The results  indicate  that occupancy of 
O~irofl3 by fibrinogen  indeed  initiates  a  process of tyrosine 
phosphorylation in platelets that precedes phosphorylation 
of ppl25 FA~. This response may require fibrinogen-induced 
oligomerization  of ct~/33 receptors  and  it  may depend  on 
the state of actin polymerization within the cell. 
Materials and Methods 
Antibodies and Other Reagents 
All monoclonal antibodies were IgGr and were purified by Staph A column 
chromatography (MAPS II; Bio-Rad Labs.,  Richmond,  CA),  except for 
PAC1 (IgMr), which was purified by boric acid precipitation and Sepharose 
4B chromatography (51). All antibodies demonstrated a single band on non- 
reduced SDS gels and two bands, representing the heavy and light chains, 
on reduced gels.  Fah fragments were prepared using immobilized papain 
(ImmunoPure Fab Preparation Kit, Pierce, Rockford, IL).  Anti-LIBS6 is 
an antibody specific for the/33 integrin subunit that induces exposure of the 
fibrinogen binding site on c~iib~33  (19). Antibody SSA6 is specific for ~3 but 
does not expose the fibrinogen receptor (1). PAC1 is specific for an activated 
conformation of am,B3 (51); 7E3  (a gift from Robert Jordan,  Centocor, 
Inc., Malvern, PA) and A2A9 are specific for the ctnbB3 complex (2,  11); 
S12,  a  gift from Rodger  McEver (Oklahoma Medical Research Founda- 
tion),  recognizes the or-granule membrane protein,  P-selectin (37);  and 
4G10 (13) and PY20 are specific for phosphotyrosine residues and were ob- 
tained from Tom Roberts (Dana Farber Cancer Institute) and ICN Bio- 
medicals, Inc. (Costa Mesa, CA), respectively. UP28 is an affinity-purified 
rabbit polyclonal antibody specific for phosphotyrosine residues (30). Poly- 
clonal  antiserum  specific  for pp125 ~^r  was  a  gift  from  Tom  Parsons, 
University  of  Virginia  (47).  The  F(ab')2  fragment  of a  goat  antibody 
specific for mouse immunoglobulin heavy and light chains was from Zymed 
Labs.,  Inc.,  South San Francisco, CA. 
Fibrinogen was purified from a commercial source (Kabi,  Stockholm, 
Sweden) (3). Analysis of purified fibrinogen on SDS-polyacrylamide gels 
under reducing conditions showed the characteristic Ate, B/~, and 3' chains 
and no contamination with von Willebrand factor or other high molecular 
weight proteins (38). Fibrinogen fragment X, a gift from Zaverio Ruggeri 
(Scripps Research Institute, La Jolla, CA), was prepared and purified as de- 
scribed previously (39, 54). It migrated as a single band with a molecular 
mass of 250 kD on nonreduced SDS gels. Peptides RGDS and "-t  4°°-4H" 
(HHLGGAKQAGDV,  single letter amino acid code) were from Peninsula 
Laboratories, Belmont, CA. Cytochalasin D was from Aldrich Chem. Co., 
Milwaukee,  WI.  All  agonists  and  platelet  inhibitors were  from  Sigma 
Chem. Co., St. Louis, MO, except for bovine thrombin (Calbiochem, San 
Diego,  CA). 
Preparation of Platelets and Induction of Fibrinogen 
Binding to ~Ub[33 
Human platelets were isolated by gel-filtration from freshly drawn blood an- 
ticoagulated with 0.15  vol NIH  formula A  acid-citrate-dextrose  solution 
supplemented with  1 #M PGE1 and 1 U/ml apyrase (57).  Unless stated 
otherwise, platelet concentration was adjusted to 2  ×  10  a platelets per ml 
in an incubation buffer containing 137 mM NaCI,  2.7 mM KC1,  1 mM 
MgC12, 5.6 mM glucose, 1 mg/ml BSA, 3.3 mM NaH2PO4, 20 mM Hepes, 
pH 7.4, and 10/~M indomethacin. To initiate fibrinogen binding to awd33, 
fibrinogen (typically 0.25 mg/ml) and anti-LIBS6 Fah (0.15  mg/ml) were 
added to the  unstirred platelet suspension (final concentration  1-1.5  × 
10S/ml)  for up to 5 rain at room temperature in a final vol of 0.3 ml. In 
some cases, fibrinogen binding was stimulated by addition of 10/zM epi- 
nephrine, 10/~M ADP, or 0.1 U/mi thrombin, instead of by anti-LIBS6 Fab. 
Unless specified otherwise, platelets stimulated by thrombin were stirred at 
1,000 rpm to cause platelet aggregation. All reactions were stopped by lys- 
ing the cells for 30 min at 4°C in radioimmunoprecipitation assay (RIPA) 
buffer containing 1% Triton X-100,  1% sodium deoxycholate, 0.1%  SDS, 
158 mM NaC1,  10 mM Tris-HC1, pH 7.2,  1 mM sodium EGTA,  1 mM 
PMSE  1 mM  Na3VO4,  and  100 kallikrein inactivator U/ml of Trasylol 
(FBA Pharmaceuticals, West Haven, CT). Lysates were then analyzed for 
phosphotyrosine-containing proteins. 
Identification of  Phosphotyrosine-containing Proteins 
All steps were at 4°C. RIPA extracts of platelets were clarified at 15,000 g 
for  30  min  and  immunoprecipitated  with  either  the  polyclonal  anti- 
phosphotyrosine antibody (UP28) (30) or the polyclonal anti-pp125  F^K an- 
tiserum (36) using Pansorbin (Calbiocbem,  La Jolla,  CA).  Rabbit anti- 
mouse  IgG  was  used  as  a  control.  The  immunoprecipitates  were  then 
washed three times in RIPA buffer, eluted from the Pansorbin in SDS sample 
buffer,  separated by  SDS-PAGE,  and transferred to nitrocellulose filters 
(36). The filters were then probed for phosphotyrosine-contalning proteins 
with a combination of the monoclonal antibodies, 4(310 and PY20 (1 t~g/ml 
each),  and protein bands containing the bound antibodies were detected 
with a  horseradish peroxidase-conjugated  goat anti-mouse IgG and the 
ECL chemiluminescence reaction (Amersham Corp.,  Arlington Heights, 
IL) (36). 
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In some experiments, oqa~3 complexes on gel-filtered platelets were cross- 
linked with primary and secondary antibodies. Gel-filtered platelets were 
resuspended to 1.9 x  10a/ml in incubation buffer and incubated for 15 rain 
at room temperature with 20/~g/ml of SSA6,  an anti-/33 monoclonal anti- 
body. Unbound SSA6 was then removed by washing as previously described 
(50), and the platelets (now 1.5  x  10S/ml)  were incubated for 20 min at 
37 ° with 25 t~g/ml of a goat F(ab')2 fragment specific for mouse immuno- 
globulin heavy and light chains. Reactions were stopped with RIPA buffer 
and the lysates analyzed  for phosphotyrosine-contalning proteins as de- 
scribed above. 
Analyses of  Platelet Function 
After the incubation of gel-filtered platelets with fibrinogen and/or anti- 
LIBS6 Fab, duplicate or triplicate 5-/~1 samples were processed  for flow 
cytometry to monitor various aspects of platelet function. Activation of inte- 
grin txnb~3 was quantitated by platelet binding of FITC-labeled PAC1 (49). 
Platelet t~-granule secretion was monitored by surface expression of P-selec- 
tin using FITC-S12 (37). The presence of platelet aggregates was assessed 
by phase-contrast microscopy, by platelet aggregometry, and by analyzing 
the forward light scatter profile of platelet particles in the flow cytometer. 
Dense granule secretion was monitored by measurement of ATP release in 
a  lumi-aggregometer  (Chronolog  Corp.,  Havertown,  PA)  (15).  Platelet 
cytosolic free calcium was measured using Fura-2/AM (Molecular Probes, 
Eugene,  OR)  with  an  Aminco-Bowman  Series  2  fluorescence  spec- 
trophotometer (SLM Instruments, Urhana, IL) (55). 
Results 
Fibrinogen Binding to Integrin ~,~33 Triggers Protein 
7)~osine Phosphorylation in Platelets 
Previous studies have shown that at least three proteins be- 
come phosphorylated on tyrosine residues when platelets 
undergo aggregation in response to agonists:  pp125 F^K, a 
125-kD  protein tyrosine kinase,  and two uncharacterized 
proteins with mobilities on SDS gels of ~100 kD (16, 22, 
36). Platelet aggregation requires both fibrinogen binding to 
axrd33 and stirring to enhance cell-cell contact. In the pres- 
ent  study, we asked whether fibrinogen binding to mrd33 
stimulates  a  process  of tyrosine  phosphorylation before 
platelet aggregation and the phosphorylation of pp125 FAK. 
Fibrinogen binding to platelets is typically stimulated by ad- 
dition of an agonist, such as thrombin. However,  agonists 
can  initiate platelet activation through multiple signaling 
pathways and can stimulate cellular responses in addition to 
aggregation, thus potentially complicating interpretation of 
protein phosphorylation experiments. Therefore, fibrinogen 
binding was induced by the Fab fragment of an antibody 
(anti-LIBS6) that binds to the/3a integrin subunit and di- 
rectly exposes the fibrinogen binding site in afro/33. Unlike 
conventional agonists, anti-LIBS6 Fab, by itself, does not 
cause detectable platelet activation (19). To further insure 
that the gel-filtered platelets used here were initially in a rest- 
ing state, they were obtained from fresh blood in the pres- 
ence of PGE~ and apyrase, and all studies were carried out 
in the presence of 10/~M indomethacin to inhibit prostaglan- 
din synthesis. 
Anti-LIBS6 Fab caused exposure of fibrinogen receptors 
on platelets in a dose-dependent fashion, as determined by 
platelet binding of FITC-PAC1, an antibody specific for the 
fibrinogen binding site in otn~3 (51) (Fig.  1).  150/zg/ml of 
anti-LIBS6 Fab stimulated FITC-PAC1 binding 15-fold, and 
this concentration of anti-LIBS6 Fab was used in further 
studies. When unstirred and unstimulated platelets were in- 
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Figure L  Effect of anti-LIBS6 Fab on platelet fibrinogen receptor 
expression. Gel-filtered platelets were prepared as described in 
Materials and Methods and incubated at 10S/ml in duplicate 50-#1 
aliquots with the indicated amounts of anti-LIBS6 Fab for 15 min 
at room temperature in the presence of 40/~g/ml of FITC-PAC1. 
Each sample was then diluted with 200/~1 of PBS and 10,000 plate- 
lets were analyzed by flow cytometry. PAC1 binding, expressed as 
the mean platelet fluorescence intensity in arbitrary fluorescence 
units, reflects exposure of the fibrinogen binding site in OtiIb~3. 
Each data point represents the mean :i: SEM of three separate ex- 
periments. 
cubated at 1.5  x  10s/mi for 5 min at 22°C, and then ana- 
lyzed on immunoblots for phosphotyrosine-containing pro- 
teins, there was basal phosphorylation of proteins at  180, 
120, 96 and 65, and 48 kD, although the intensity of these 
bands varied from experiment to experiment. Similar results 
were  obtained  when  platelets  were  incubated  with  anti- 
LIBS6 Fab alone or 0.25 mg/ml fibrinogen alone (Fig. 2, lanes 
1-3). In contrast, when platelets were incubated with both 
anti-LIBS6  Fab  and  fibrinogen, additional protein  bands 
with molecular masses of 50-68  kD and 140 kD became 
phosphorylated (Fig. 2, lanes 4-6). 
Phosphorylation of these proteins was maximal at 0.25 
mg/ml of fibrinogen, a concentration of ligand known to sat- 
urate platelet fibrinogen receptors (3). This phosphorylation 
was prevented by an anti-otto,3 antibody (7E3  Fab) known 
to inhibit fibrinogen binding (Fig. 2, lane 7) (11). None of 
the  phosphorylated bands  induced by  fibrinogen binding 
comigrated with either purified fibrinogen or anti-LIBS6 Fab 
fragments on reduced SDS gels (not shown). 
Several additional characteristics of the phosphorylation 
response to fibrinogen binding were studied. The 50-68-kD 
and  140-kD  proteins  became phosphorylated on tyrosine 
residues  within  30  s  of addition of anti-LIBS6 Fab  and 
fibrinogen to the platelets. The extent of phosphorylation in- 
creased over 5 min (Fig. 3). This delay in phosphorylation 
was at least partially due to the time required for antibody 
and fibrinogen binding. In platelets from an individual with 
homozygous Glanzmann's thrombasthenia (which expressed 
~5 % the normal amount of a~r~3), the phosphorylation re- 
sponse was barely detectable, with only minimal phosphory- 
lation after a 5-rain incubation (Fig. 3). 
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ylation in platelets. Unstirred gel-filtered platelets were incubated 
for 5 min at room temperature in the absence of fibrinogen or anti- 
body (lane/), in the presence of 0.25 mg/ml fibrinogen (lane 2), 
or in the presence of 0.15 mg/ml anti-LIBS6 Fab (lane 3). In lanes 
4-6, platelets were incubated with the anti-LIBS6 Fab in the pres- 
ence of increasing amounts of fibrinogen (0.05 mg/ml, 0.25 mg/ml, 
and  1.0 mg/ml, respectively).  In lane 7, anti-LIBS6 Fab and 0.25 
mg/ml fibrinogen were present  along with 20/zg/ml of antibody 
7E3 Fab, an anti-c'nb/33 antibody that inhibits fibrinogen binding. 
In lane 8, platelets were aggregated by stirring for 5 min in the pres- 
ence of 0.1  U/ml thrombin.  After each incubation,  platelets were 
lysed  in  RIPA buffer  and  immunoprecipitated  with  an  affinity- 
purified polyclonal anti-phosphotyrosine antibody (UP 28). Immu- 
noprecipitated  proteins were separated by SDS-PAGE and probed 
on immunoblots with two monoclonal antibodies specific for phos- 
photyrosine  residues,  as described  in Materials  and Methods.  In 
this  and  some subsequent  figures, an arrow  identifies a  140-kD 
phosphoprotein  and  a bracket identifies  50-68  kD phosphopro- 
teins. 
Several  observations  indicated  that  this  tyrosine  phos- 
phorylation response of normal platelets was independent of 
platelet aggregation. First, the extent of tyrosine phosphory- 
lation was unaffected by varying the platelet concentration 
over a  10-fold range (108-109/ml) during the incubation with 
fibrinogen. Second, platelet aggregation was avoided by not 
stirring, and no aggregation could be seen by phase-contrast 
microscopy, platelet aggregometry, or flow cytometry. Third, 
phosphorylation of the 50-68-kD and  140-kD proteins was 
observed even in the presence of 5/zM prostacyclin, an in- 
hibitor of agonist-mediated platelet activation and aggrega- 
tion (Fig. 4). Fourth, the previously described pair of phos- 
phoproteins  of '~100  kD  which  are  phosphorylated  after 
thrombin-induced platelet aggregation were not observed in 
unstirred platelets treated with anti-LIBS6 Fab and fibrino- 
gen (compare Fig. 2, lanes 4-6 with platelets in lane 8 that 
were aggregated in response to thrombin and stirring). 
The tyrosine phosphorylation response induced by anti- 
Figure 3. Time course of tyrosine phosphorylation  in normal and 
Glanzmann's thrombasthenia platelets. Unstirred gel-filtered plate- 
lets from a normal donor (lanes 1-4) or from a donor with Glanz- 
mann's thrombasthenia (lanes 5-8) were incubated with fibrinogen 
alone (lanes 1 and 5) or with fibrinogen (0.25 mg/ml),  and anti- 
LIBS6 Fab (0.15 mg/ml) for the indicated periods of time, and then 
lysed in RIPA buffer. Phosphotyrosine-containing proteins were de- 
tected as in Fig. 2. 
LIBS6  Fab  and  fibrinogen  was  not  associated  with  bulk 
secretion from platelet dense granules, as monitored by ATP 
release, or secretion from a-granules, as monitored in flow 
cytometry by surface expression of the a-granule membrane 
protein, P-selectin (not shown). In addition, phosphorylation 
could not be attributed to the release of ADP, an endogenous 
agonist,  from platelet dense granules  because it occurred 
even in  the  presence of apyrase or pyruvate kinase/phos- 
phoenolpyruvate, enzyme systems that  remove ADP (Fig. 
4). Tyrosine phosphorylation in response to anti-LIBS6 Fab 
and  fibrinogen  was  not  associated  with  a  measurable  in- 
crease  in  cytoplasmic free calcium,  as  detected  with  the 
calcium-sensitive fluorescent probe,  Fura-2,  either  in  the 
presence or absence of 1 mM CaCl2  (not shown).  Finally, 
phosphorylation was not uniquely dependent on the method 
of  activation  of  Ctm~3 since  it  was  also  observed  when 
fibrinogen binding to unstirred platelets was induced by con- 
ventional agonists, such as epinephrine, ADP, or thrombin 
instead of by anti-LIBS6 Fab (Fig. 5). Taken together, these 
results indicate that tyrosine phosphorylation of the 50-68- 
kD  and  140-kD  proteins  in  platelets  requires  fibrinogen 
binding to Otnb/33, but it does not require platelet aggregation 
or secretion. 
lntegrin-mediated ~ffosine Phosphorylation Is 
Initiated before Phosphorylation of  ppl25  FAr 
In fibroblasts or human carcinoma cells spread on fibronec- 
tin, pp125  FAK localizes to integrin-rich focal adhesions and 
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sine phosphorylation.  Unstirred  gel-filtered platelets were incu- 
bated in the absence of antibody or fibrinogen (lane/), in the pres- 
ence of 0.25 mg/ml fibrinogen (lane 2), or in the presence of 0.15 
mg/ml anti-LIBS6 Fab (lane 3).  In lanes 4-7, platelets were in- 
cubated with both fibrinogen and anti-LIBS6 Fab in the absence of 
an inhibitor (lane 4), or with 5 #M PGI2 (lane 5), 10 U/ml apyrase 
(lane 6), or a combination of 14.3 U/ml pyruvate kinase and 1 mM 
phosphoenolpyruvate (lane 7). After 5 min, platelets were lysed in 
RIPA buffer  and  phosphotyrosine-containing  proteins  were  de- 
tected as in Fig. 2. In preliminary experiments in which binding 
of FITC-PAC1 was used as a marker for platelet activation, these 
concentrations of inhibitors inhibited ADP-induced platelet activa- 
tion by ~95 %. Furthermore, platelet activation in response to epi- 
nephrine or thrombin was inhibited by PG12 but not by the ADP 
scavengers. 
becomes phosphorylated on tyrosine residues, thus implicat- 
ing this tyrosine kinase in integrin-mediated signaling events 
(7, 23,  33,  34, 47). pp125  F~ also becomes phosphorylated 
on  tyrosine  residues  and  activated  after  agonist-induced 
platelet  aggregation  or  after  spreading  of platelets  on  a 
fibrinogen matrix (36) (24a). Fig. 6 shows that phosphoryla- 
tion of pp125  F~ did not occur in unstirred platelets under 
conditions  where  anti-LIBS6  Fab  and  fibrinogen  caused 
phosphorylation of the 50-68-kD and 140-kD proteins. This 
finding suggests that pp125  F~x is not the kinase responsible 
for phosphorylation of the 50-68-kD and 140-kD substrates. 
As expected, pp125 F~ became phosphorylated when plate- 
lets were stirred and allowed to form large aggregates in re- 
sponse to thrombin (Fig. 6) or to maximal concentrations of 
ADP or epinephrine (not shown). In contrast, when platelets 
were stirred in the presence of anti-LIBS6 Fab and fibrino- 
gen, they formed only small aggregates, and phosphoryla- 
tion of pp125 F^K was not observed unless the platelets were 
simultaneously treated with sub-threshold concentrations of 
a  conventional agonist,  such as  epinephrine (not shown). 
These experiments suggest that fibrinogen binding to c~nb/3~ 
results in sequential tyrosine phosphorylation: "early" reac- 
tions occur directly upon ligation of the fibrinogen receptor 
and include phosphorylation of 50-68 kD and 140 kD sub- 
strates; later reactions are associated with platelet aggrega- 
tion or spreading and include phosphorylation of pp125  F^K 
and a pair of substrates of ~100 kD. Although phosphoryla- 
tion of pp125  F~ is dependent on fibrinogen-mediated plate- 
let aggregation, additional agonist-induced platelet reactions 
appear to be required. 
Integrin-mediated 1)cosine Phosphorylation  Depends 
on the State of  Actin Polymerization 
Thrombin-induced platelet aggregation leads to actin poly- 
merization and  to  enrichment of otrd33 within  the  actin- 
rich, Triton X-100-insoluble, "cytoskeletal"  fraction of  plate- 
lets (63).  Also enriched within this fraction are structural 
proteins, such as vinculin, and potential regulatory proteins, 
such  as  PI3-kinase  and  pp60  s~  (10, 29,  63).  Although 
fibrinogen binding to c~nb/33 presumably represents a  more 
Figure 5. Agonist-induced fibrinogen binding causes 
tyrosine phosphorylation of a 140-kD protein in un- 
stirred platelets. Unstirred gel-filtered platelets were 
incubated alone (lane/), or in the presence of 0.25 
mg/ml fibrinogen, and various agonists as indicated. 
The concentration of epinephrine was 50 t,M, ADP 
20 ~M, and thrombin 0.1 U/ml. In lane 9, antibody 
A2A9 (20/zg/ml),  specific for c~n~83, was added to 
inhibit fibrinogen binding. After 5 min, the platelets 
were lysed in RIPA buffer and phosphotyrosine-con- 
taining proteins were detected as in Fig. 2. 
Huang  et al. Integrin-mediated  Tyrosine  Phosphorylation  4"/7 Figure 6. Fibrinogen binding to platelets is not sufficient to induce 
tyrosine phosphorylation of pp125  FAK. In both the left and fight 
hand panels, unstirred gel-filtered platelets were incubated in the 
absence of  antibody or fibrinogen (lane/), with 0.25 mg/ml fibrino- 
gen (lane 2), or with fibrinogen and 0.15 mg/ml anti-LIBS6 Fab 
(lane 3). In lane 4, platelets were stirred in the presence of  0.1 U/ml 
thrombin. After 5 min, platelets were lysed in RIPA buffer and 
those in the left hand panel were analyzed for phosphotyrosine- 
containing proteins as in Fig. 2. Platelets in the fight hand panel 
were immunoprecipitated with anti-pp125  F^K polyclonal rabbit se- 
rum, and the immunoprecipitated proteins were then analyzed on 
immunoblots for phosphotyrosine residues. 
Figure 7. Effect of cytochalasin D on protein tyrosine phosphoryla- 
tion in platelets. After gel-filtration, platelets were incubated for 10 
min at room temperature with either 10/zM cytochalasin D (CD) 
(lanes 2,  4,  6, and 8) or 0.3% DMSO, the diluent used for the 
cytochalasin D (lanes 1, 3, 5, and 7). Then, unstirred platelets were 
incubated for 5 more min in the absence of antibody or fibrinogen 
(lanes I and 2), in the presence of 0.25 mg/ml fibrinogen (lanes 3 
and 4), or with fibrinogen and 0.15 mg/ml anti-LIBS6 Fab (lanes 
5 and 6). In lanes 7 and 8, platelets were stirred for 5 min in the 
presence of 0.1 U/ml thrombin. Reactions were stopped with RIPA 
buffer and phosphotyrosine-containing proteins were detected as in 
Fig. 2. 
subtle stimulus to platelets than does thrombin,  we asked 
whether the state of actin polymerization might influence 
t~ird33 mediated tyrosine phosphorylation. Fibrinogen bind- 
ing was studied in the presence of 10/~M cytochalasin D, 
which reduces the state of actin polymerization in the cell. 
Cytochalasin D markedly inhibited phosphorylation of the 
50-68 kD and  140 kD substrates when fibrinogen binding 
was stimulated by either anti-LIBS6 Fab or thrombin (illus- 
trated in Fig.  7  for the  140-kD substrate).  In platelets ag- 
gregated by thrombin, cytochalasin D  also inhibited phos- 
phorylation of the pair of ~100 kD "aggregation-dependent" 
substrates (Fig. 7). Cytochalasin D at this concentration in- 
hibited the binding of fibrinogen to platelets treated with 
thrombin or anti-LIBS6 Fab by 25-30% (not shown). How- 
ever, this partial inhibition of ligand binding could not explain 
the almost complete inhibition of tyrosine phosphorylation 
by cytochalasin D, thus implicating actin polymerization in 
the process of tyrosine phosphorylation. 
That fibrinogen binding might be influencing the state of 
actin polymerization in the platelet was suggested further by 
experiments evaluating the reversibility of ligand binding to 
o~ird33. When platelets are activated by agonists,  a  fraction 
of the fibrinogen (or antibody PAC1) which becomes bound 
cannot be displaced from the cells by addition of 10 mM 
EDTA.  This process of irreversible binding is progressive 
over time and appears to require actin polymerization (41). 
When FITC-PAC1  binding to platelets was stimulated with 
anti-LIBS6 Fab, the amount of irreversibly bound PAC1 in- 
creased significantly over time (P < 0.01) (Fig. 8). Taken to- 
gether with the cytochalasin D  results,  this  suggests  that 
tyrosine phosphorylation in platelets may be influenced by 
the state of actin polymerization after fibrinogen binding to 
O/lib'3. 
Integrin-mediated ~yrosine Phosphorylation 
Requires l~brinogen Receptor Occupancy by a 
Multimeric Ligand 
Fibrinogen is a dimeric molecule with at least three potential 
a~rd~3 recognition sites:  two RGD-containing sequences in 
the Aot chain at positions 95-97 and 572-575, and a short 
linear  sequence  at  the  carboxy  terminus  of the  3,-chain 
('y4~-41~) (43). Because fibrinogen is multivalent, we asked 
whether tyrosine phosphorylation triggered by the binding of 
this  ligand might require the cross-linking of am~3  com- 
plexes. As an initial approach to this question, the ability of 
fibrinogen fragment X to support tyrosine phosphorylation 
was  studied.  Fragment X  is  a  dimeric,  250  kD  plasmin- 
derived fragment of fibrinogen that lacks Aot572_575 but still 
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PAC1 to platelets in response to thrombin or 
anti-LIBS6 Fab. Platelets were incubated at 
room temperature with 40/tg/ml FITC-PAC1 
for 5 min (black bars) or 45 rain (stippled bars) 
in the presence of either no agonist, 0.1 U/ml 
thrombin, or 0.15 mg/ml anti-LIBS6  Fab. Then 
triplicate 50-#1 aliquots were incubated with 
buffer  alone or buffer  containing 10 mM EDTA 
for 5 additional min, and FITC-PAC1 binding 
was determined by analyzing 10,000 platelets 
per sample by flow cytometry. PAC1 binding is 
expressed as mean platelet fluorescence inten- 
sity in arbitrary fluorescence  units. Irreversible 
FITC-PAC1 binding was defined as binding in 
the presence of EDTA. Reversible FITC-PAC1 
binding was defined as binding in the absence 
of EDTA minus irreversible binding. Data rep- 
resent means 5: SEM of three independent ex- 
periments. 
contains the Actg~_97 and 3'4ar-4H cell recognition sites (9). 
Addition of fragment X at 0.5 mg/ml to gel-filtered platelets 
did not stimulate tyrosine phosphorylation, presumably be- 
cause it did not bind to these resting cells. However,  when 
the binding of fragment X to a~rb~3 was stimulated by anti- 
LIBS6 Fab, tyrosine phosphorylation of the 50-68-kD and 
140-kD  proteins was observed (Fig. 9). 
In contrast to the results with fragment X, two short mono- 
meric peptides derived from the cell recognition sequences 
in fibrinogen, RGDS, and "y4~o-4~,  failed to stimulate tyrosine 
phosphorylation, either in the absence or presence of anti- 
LIBS6 Fab (Fig.  10). This result could not be explained by 
a lack of binding of these peptides to c~n~3 since each pep- 
tide inhibited tyrosine phosphorylation induced by fibrino- 
gen (Fig. 10). Inasmuch as platelet aggregation did not occur 
in these experiments, the requirement for a dimeric ligand 
for cell signaling may reflect the need for ligand-induced 
oligomerization of ctm~3 complexes within individual plate- 
lets.  Consistent with this  interpretation,  when Ctir,  fl3  was 
cross-linked by a primary 133 mouse monoclonal antibody 
(SSA6) and the F(ab')2 fragment of a  secondary goat anti- 
body specific for mouse immunoglobulins, tyrosine phos- 
phorylation of the 50-68-kD and 140-kD  proteins was ob- 
served, even in the absence of  added fibrinogen (Fig. 11), and 
even when 1 mM RGDS was added to prevent fibrinogen 
binding (not shown).  A  F(ab')2 fragment was used as the 
secondary antibody in this experiment to prevent signaling 
through the platelet Fc~RII receptor.  The lack of tyrosine 
phosphorylation of this 40-kD receptor confirms that it was 
not involved in any of the foregoing results (30). 
Discussion 
The present studies demonstrate that a process of protein 
tyrosine phosphorylation is triggered in platelets when fibrino- 
gen, a dimeric and multivalent adhesive ligand, binds to inte- 
grin O~n~/~3. The initial phosphorylation is restricted to sub- 
strates with mobilities on reduced SDS gels of  50-68 kD and 
140 kD. It occurs within seconds of fibrinogen binding, and 
it is observed whether ligand binding is stimulated by a con- 
ventional agonist or by the Fab fragment of a/33 antibody 
(anti-LIBS6)  that  causes  direct  exposure  of the  platelet 
fibrinogen receptor. In contrast to tyrosine phosphorylation 
of the focal adhesion kinase, pp125 F~x, phosphorylation of 
the 50-68 kD and 140 kD substrates does not require platelet 
aggregation, nor is it dependent on prostaglandin synthesis, 
a  change in the cytosolic free calcium concentration,  or 
granule secretion. As a result,  the 50-68-kD  and  140-kD 
substrates are phosphorylated before the phosphorylation of 
pp125 F~,  making  it unlikely that  this  tyrosine  kinase is 
responsible for their phosphorylation. Studies using well- 
characterized,  plasmin-derived fragments of fibrinogen as 
well as peptides derived from the cell recognition domains 
of fibrinogen indicate further that tyrosine phosphorylation 
in response to the binding of soluble fibrinogen requires the 
dimeric form of this ligand, suggesting a  role for integrin 
oligomerization in the signaling process. In addition, studies 
with  cytochalasin D  indicate  that  the  earliest  phases  of 
integrin-mediated tyrosine phosphorylation in platelets may 
depend on the state of actin polymerization in the cell. 
Although resting platelets can adhere constitutively to im- 
mobilized fibrinogen through Otm~3, unstimulated platelets 
cannot bind fluid-phase fibrinogen (3, 46).  However,  when 
platelets  are  exposed to  damaged vascular surfaces,  they 
come in contact with agonists that activate these cells and 
cause a  conformational change in ot~3  that increases  its 
apparent affinity for fibrinogen to a Kd of ,,o0.05 mg/ml (3, 
52). This process of inside-out signaling involves the action 
of GTP-binding proteins, protein kinase C, and possibly pro- 
tein tyrosine kinases (50). It serves to prevent the interaction 
of platelets with fibrinogen in the circulation, yet it provides 
for rapid binding of fibrinogen to platelets in the vicinity of 
a vascular wound. Although regulation of the affinity state 
of eta3 is clearly beneficial to the organism, it presented a 
technical  challenge  to  us  in  the  present  study since  we 
wanted to focus on signaling events distal to fibrinogen bind- 
ing. Had we chosen to only activate platelets with a conven- 
tional agonist in order to expose the fibrinogen receptors, 
any resultant changes in the levels of protein tyrosine phos- 
phorylation might have been due to  agonist activation of 
metabolic pathways unrelated to those triggered by fibrino- 
gen binding. 
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tyrosine phosphorylation in platelets. Unstirred gel-filtered plate- 
lets were incubated as indicated with 0.15 mg/ml anti-LIBS6 Fab, 
0.25 mg/ml fibrinogen, 1 mM RGDS, or 5 mM 3~,0o_¢n. In lane 9, 
platelets were stirred in the presence of 0.1 U/ml thrombin. After 
5 min, all samples were lysed in RIPA buffer and phosphotyrosine- 
containing proteins were detected as in Fig. 2. 
Figure 9. Effect of fibrinogen fragment X on protein tyrosine phos- 
phorylation  in platelets.  Unstirred  gel-filtered platelets were in- 
cubated in the absence of antibody or ligand (lane/), in the pres- 
ence of  0.25 mg/ml fibrinogen (lane 2), 0.15 mg/ml anti-LIBS6 Fab 
(lane  3),  anti-LIBS6 Fab  plus  fibrinogen  (lane  4),  0.5  mg/ml 
fibrinogen fragment X (lane 5), or anti-LIBS6 Fab plus fragment 
X (lane 6).  After 5 min,  the reactions were stopped with RIPA 
buffer and phosphotyrosine-contalning proteins were detected as in 
Fig. 2. 
To overcome this problem, the fibrinogen binding site in 
am~3 was exposed by the Fab fragment of anti-LIBS6. The 
Fab fragment was used instead of the intact immunoglobulin 
to insure that platelets were not activated by ligation of the 
Fc-yRII receptor. Ligation of  this 40-kD receptor on platelets 
is known to be associated with its phosphorylation on tyro- 
sine residues (30). No such phosphorylation was observed 
in  our  experiments.  Anti-LIBS6  Fab  caused  fibrinogen 
receptor exposure in a dose-dependent fashion, as monitored 
by flow cytometry using  the activation-specific anti-ottIb~3 
antibody, PAC1. Anti-LIBS6 Fab did not, however, induce 
platelet tyrosine phosphorylation unless fibrinogen was pres- 
ent. Fibrinogen-dependent phosphorylation of  the 50-68-kD 
and 140-kD platelet proteins was not dependent on the par- 
ticular method used to expose fibrinogen receptors since it 
was also observed when agonists, such as epinephrine, ADP, 
or thrombin were used instead of anti-LIBS6 Fab to activate 
O~rd~3. Of note, the ligand-binding function of integrins in 
other ceils is also subject to regulation (20, 31). Thus, devel- 
opment of "activating antibodies" similar in function to anti- 
LIBS6  may  prove  generally  useful  in  studying  integrin- 
mediated signaling reactions. 
Several results indicated that the binding of a dimeric form 
of the fibrinogen molecule was necessary to initiate tyrosine 
phosphorylation through otlrd33. Binding of fibrinogen frag- 
ment X, which like fibrinogen is dimeric also caused tyro- 
sine phosphorylation. In contrast, the monomeric fibrino- 
gen-derived cell recognition peptides,  RGDS  and  "g~o-4., 
failed to cause phosphorylation, despite the fact that they 
bound to the fibrinogen receptor, as indicated by their ability 
to  inhibit  fibrinogen-dependent tyrosine phosphorylation. 
Each  half-molecule of fibrinogen  contains  at  least  three 
potential  recognition  domains  for  a~r~3 (3'400-4. and  two 
RGD-containing sequences at Aot95_97 and Atxs?2-574). In this 
sense, even a fibrinogen monomer may be multivalent. Why 
then would a fibrinogen dimer be required for signaling? A 
dimeric ligand might be necessary to either cross-link Ct]rd$3 
complexes on adjacent platelets or to induce oligomerization 
of such complexes on the surface of individual platelets. 
It could be argued that fragment X caused signaling not 
because it is dimeric but because it retains both the RGD se- 
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tyrosine phosphorylation in platelets. Gel-filtered platelets were 
initially incubated in the presence or absence of 20 #g/ml SSA6, an 
anti-~/3 monoclonal antibody (labeled "1  ° Ab" in the figure). Plate- 
lets were then washed by centrifugation in the presence of PG12 
and apyrase to remove unbound primary antibody. Some of the 
samples were then incubated for 20 min at 37°C with 25 #g/ml of 
a goat F(at¢)2 fragment specific for mouse immunoglobulins (la- 
beled "2  ° Ab" in the figure)  to cross-link the primary antibody.  Dur- 
ing this second incubation, some of  the samples  were also incubated 
with 0.15 mg/rnl anti-LIBS6 Fab and 0.25 mg/ml fibrinogen. Reac- 
tions were stopped with RIPA buffer and the lysates analyzed for 
phosphotyrosine-containing  proteins as described in Fig. 2. 
quence at Aot95-97 and the 7~o~. sequence. This interpreta- 
tion is unlikely for several reasons. First, work with mutant 
forms  of recombinant  fibrinogen has  shown  that  neither 
A0/95-97 nor  A0/572-574 is  necessary for platelet aggregation 
(14). Second, isolated fibrinogen 3,-chain multimers can sup- 
port aggregation (27).  Third, binding of RGDS to platelets 
did not initiate tyrosine phosphorylation. Thus, it is more 
likely that fragment X induced signaling because a dimeric 
form  of fibrinogen  is  required  to  cross-link  etch3  com- 
plexes. This notion is supported by the fact that cross-linking 
of cirri3  complexes  with antibodies  also  caused  tyrosine 
phosphorylation of the 50-68-kD  and  140-kD  proteins in 
platelets, even in the absence of fibrinogen binding. 
These studies do not completely resolve whether signaling 
requires  fibrinogen to cross-link the receptor on adjacent 
platelets or whether it requires integrin oligomerization on 
the surface of individual platelets. Unfortunately, techniques 
to  detect  reversibly  associated  receptor  oligomers  in  the 
membranes of single cells are not well developed. However, 
the experimental conditions used in the present experiments 
(e.g., no stirring and a platelet concentration of 1-1.5 x  l0  s 
cells/ml) do not favor platelet-platelet interaction. Indeed, 
no platelet aggregates were detected by phase-contrast mi- 
croscopy,  aggregometry, or  flow cytometry. If fibrinogen 
were to cause oligomerization of OtnbB3 within the plane of 
the plasma membrane as a  prerequisite to  signaling, this 
would be analogous in some ways to the initial phases of sig- 
naling induced by the binding of certain growth factors to 
their receptors (59).  In contrast to growth factor receptors, 
however, integrin subunits contain no intrinsic protein tyro- 
sine kinase activity. Thus, integrin-mediated cell signaling 
may be more analogous to the process of signaling in T and 
B cells, where ligation of cell surface receptors stimulates 
tyrosine phosphorylation through the physical interaction of 
activated receptors with non-receptor tyrosine kinases of the 
Src family (4).  Although platelets contain several tyrosine 
kinases (4), the kinase(s) responsible for fibrinogen-depen- 
dent phosphorylation of the 50-68-kD and 140-kD proteins 
remains to be identified. 
The inhibition of  fibrinogen-dependent tyrosine phosphor- 
ylation in platelets by cytochalasin D suggests a role for actin 
polymerization in early signaling events triggered through 
ct~B3. Resting platelets contain short actin filaments which 
associate via actin-binding protein to a  spectrin-rich sub- 
membrane  lamina  (5,  26).  Actin-nucleating  activity  in- 
creases after agonist-induced platelet activation or during 
platelet spreading on a surface (25).  During platelet spread- 
ing, mature cytoskeletal structures analogous to focal adhe- 
sions are formed (40).  Since the binding of soluble fibrino- 
gen to platelets does not cause platelet aggregation unless 
stirring takes place, any actin assembly triggered by ligand 
binding to otm~3 would be expected to be more subtle than 
that induced during aggregation or spreading. Nonetheless, 
it is plausible that fibrinogen binding might stimulate the for- 
mation of nascent, actin-rich structures through the interac- 
tion of the integrin ~3  subunit with actin-binding proteins 
such as ot-actinin or talin (58). It may be pertinent in this re- 
gard  that  pp60  c-sRc has  been  shown  to  partition  to  the 
detergent-insoluble "cytoskeletal" fraction of platelets after 
thrombin  treatment,  but  this  does  not occur  in  platelets 
deficient in otm~83 (10).  Thus, ligand-induced oligomers of 
O/lib'3 may function as sites of nucleation for structural and 
regulatory proteins of the platelet cytoskeleton. 
Although we could detect no generalized increase in plate- 
let cytoplasmic free calcium in response to anti-LIBS6 Fab 
and fibrinogen, it is  still theoretically possible that Otnb~3 
plays a role in cytoskeletal organization and tyrosine phos- 
phorylation  by regulating localized calcium influx (6). When 
heterologous cells transfected with wild-type ot~rd~3 become 
adherent to fibrinogen, they stimulate cytosolic calcium os- 
cillations, followed by tyrosine phosphorylation of a 125-kD 
protein (42).  Although integrin subunits do not exhibit the 
multiple transmembrane domains typical of many ion chan- 
nel  proteins,  a  protein  with  such  a  structure  has  been 
reported to be associated with a/~3-related integrin in leu- 
kocytes (Lindberg, E, and E. J.  Brown.  1992.  MoL  BioL 
Cell.  3:95a). 
On the basis of the existing data, we propose a model of 
integrin-mediated signaling in platelets in which binding of 
fibrinogen causes oligomerization of Ot~rd33 within the plane 
of the plasma membrane, leading to actin assembly in prox- 
imity to these oligomers. During this process, one or more 
protein tyrosine kinases and their potential substrates might 
become  localized  to  these  regions,  presumably  through 
specific protein-protein interactions. Once juxtaposed to the 
appropriate enzyme(s), substrates such as the 50-68-kD and 
140-kD proteins would become phosphorylated on tyrosine 
residues.  After this initial phase,  additional enzymes and 
substrates, for example pp125 F^K, might be drawn into the 
cytoskeleton  during  subsequent  platelet  aggregation  or 
spreading. In this model, phosphorylation and activation of 
pp125 FAK would occur after other integrin-mediated phos- 
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gestion that pp125 F^x represents a point of convergence for 
phosphorylation reactions that follow ligation of integrins 
and neuropeptide receptors (33, 62). It is also consistent with 
the finding that pp125 F^x is phosphorylated after platelet 
adhesion to collagen in a reaction that involves the collagen 
receptor, ¢x2Bt, but not O[Ilb~3 (24a). 
As shown here and as demonstrated previously (36), tyro- 
sine phosphorylation of pp125 F^x occurs when platelets ag- 
gregate in response to maximal concentrations of agonists, 
such as  thrombin.  Phosphorylation of pp125F¢  x also  was 
observed when platelets were allowed to aggregate in re- 
sponse to the combination of fihrinogen, anti-LIBS6 Fab, 
and a  subthreshold concentration of epinephrine.  In con- 
trast, no phosphorylation of pp125 F^K ocCUlTed when plate- 
lets were stilTed in the presence of this concentration of epi- 
nephrine alone or the fibrinogen/anti-LIBS6 Fab alone. This 
suggests that fibrinogen- and czm,  B3-mediated platelet aggre- 
gation  is  necessary but not sufficient for pp125 FAx phos- 
phorylation. Rather, additional agonist-induced platelet re- 
actions seem to be required. A similar conclusion has been 
reached  in  studies  of platelet  adhesion  to  immobilized 
fibrinogen,  where pp125 FAx phosphorylation requires  ini- 
tial  interaction of the fibrinogen with o~mfl3, followed by 
platelet spreading and the release of small amounts of ADP 
from the cells (24a). These findings with platelets may have 
implications for the mechanisms of integrin-mediated tyro- 
sine phosphorylation of pp125 F^K in other cell types. 
Several questions can now be posed based on the observa- 
tion that tyrosine phosphorylation in platelets is triggered 
directly by binding of a soluble adhesive ligand to integrin 
OliroB3. Do adhesive ligands other than fibrinogen, such as 
fibronectin, vWf, or vitronectin, induce signaling when they 
bind to cxnbB3? Is the tyrosine phosphorylation caused by 
stimulation of a tyrosine kinase or by inhibition of a tyro- 
sine phosphatase? What are the identities and functions of 
the  50-68-kD  and  140-kD  substrates  that become  phos- 
phorylated directly after fibrinogen binding? Why is platelet 
aggregation or spreading required for ¢X~r~3-mediated tyro- 
sine  phosphorylation of pp125FAX7 The  answers  to  these 
questions may shed additional light on the regulatory role 
of integrin adhesion receptors  in cell spreading, motility, 
growth, and differentiation. 
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